Carrer Antic Camí de Tordera 109, 119
+34 93 490 4908
Bioiberica is a global Life Science company specialised in the identification, extraction and development of biomolecules of high biological and therapeutic value for the pharmaceutical and nutraceutical industries. Over the last 40 years, this specialisation has positioned Bioiberica as the leading Heparin API manufacturer and a world reference in the research, production and sale of other animal-derived APIs and ingredients. These include:
Heparin – the most used anticoagulant blood thinner globally, which now saves more than 100 million lives every year the world over.
Thyroid – natural origin thyroid API extracted from porcine thyroid glands, used to treat hypothyroidism and its associated symptoms – a condition characterised by a low volume of thyroidal hormones. It is meant to replace or supplement the hormones that are ineffectively produced by the human thyroid gland. Bioiberica’s thyroid API is entirely of European origin.
Chondroitin sulphate – a specific glycosaminoglycan used for the symptomatic treatment of osteoarthritis. Clinical trials demonstrate its effectiveness in reducing joint pain and increasing mobilityi,ii. Bioiberica’s chondroitin sulphate is the chemical reference substance in the EU and US pharmacopoeias and is obtained from various animal sources.
Glucosamine – an amino sugar precursor of glycosaminoglycans, used for the symptomatic treatment of mild knee osteoarthritis. Clinical trials demonstrate its ability to reduce joint pain and improve mobilityiii. Glucosamine supplied by Bioiberica is produced by hydrolysis of crustacean shells and is available for sale in the form of any of its salts.
Aside from its specialisation in substances of animal origin, Bioiberica’s production capacity, supply chain model and vertical integration guarantee full traceability, security and sustainability making it a trusted partner with which to grow and innovate.
In addition, the company’s commitment to international standards and industrial excellence means it delivers API quality, safety and regulatory compliance too.
Bioiberica is always looking for opportunities to partner with others – to help them innovate by providing the scientific, regulatory, industrial and market expertise they need to do their best work. With the creation of tailor-made products, pilot manufacturing, scaling services, development of analytical methods to characterise complex molecules and regulatory expertise, Bioiberica is committed to supporting its partners’ business development.
To support future innovation in healthcare, Bioiberica actively seeks new strategic partnerships to kickstart exciting developments in the following areas:
Let’s activate to innovate!
i Bruyère O, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63.
ii Rillo O, et al. PANLAR Consensus Recommendations for the Management in Osteoarthritis of Hand, Hip, and Knee. J Clin Rheumatol. 2016 Oct;22(7):345-54.
iii Ogata T, et al. Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis Clin Rheumatol. 2018 Sep;37(9):2479-2487.